Clinical Psychopharmacology and Neuroscience 2008; 6(2): 75-78  
Resolution of Tardive Dyskinesia Following a Switch
from Long-Acting Injectable Risperidone to Aripiprazole
Sung-Wan Kim1,2, Sam-Yeon Lee1, Jae-Min Kim1,2, Il-Seon Shin1,2, Su-Jin Yang1,2, Jin-Sang Yoon1,2
1Department of Psychiatry, Chonnam National University Medical School, Gwangju,
2Clinical Trial Center and Depression Clinical Research Center, Chonnam National University Hospital, Gwangju, Korea
© The Korean College of Neuropsychopharmacology. All rights reserved.

Tardive dyskinesia (TD) is a serious neurological side effect of antipsychotics. Dopaminergic hypersensitivity mediated by the upregulation of the D2 receptor with prolonged dopamine blockade is thought to play a key role in the development of neurolepticinduced TD. Aripiprazole, a partial dopamine agonist, causes little dopamine up-regulation; therefore, it may be associated with a lower risk of TD. We present a literature review and a case in which a schizophrenic patient developed TD while using longacting injectable risperidone, which was completely resolved following a switch to aripiprazole. The resolution of TD in this patient was sustained during 22 months of follow-up treatment with aripiprazole. Aripiprazole may be an effective treatment option for patients who suffer from neuroleptic-induced TD.
Keywords: Tardive dyskinesia; Schizophrenia; Aripiprazole; Long-acting injectable risperidone.

This Article

Close ✕

Cited By Articles
  • CrossRef (0)
  • Scopus (0)
  • Download (613)

Social Network Service